A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

Clinical trial NCT01729754 · COMPLETED

Trial details

NCT number: NCT01729754
Sponsor: Sun Pharmaceutical Industries Limited
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2013-02-05
Primary completion: 2015-09-28
Enrollment: 1090

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.